Welcome to our dedicated page for SMITH & NEPHEW PLC SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SMITH & NEPHEW PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SMITH & NEPHEW PLC's regulatory disclosures and financial reporting.
Smith+Nephew plans to announce its second quarter trading and first half 2026 results for the period ended 27 June 2026 on 4 August 2026 at 7.00am BST / 2.00am EDT. A conference call for financial analysts will follow at 11.30am BST / 6.30am EDT. The company is a global medical technology business with 17,000 employees, operating in around 100 countries, and generated annual sales of $6.2 billion in 2025.
Smith & Nephew plc discloses a TR-1 notification that an investor group controlled by Bank of America Corporation holds 3.172736% of its voting rights. This comprises 2.402237% through shares representing 20,216,881 voting rights and 0.770499% through financial instruments over 6,484,406 voting rights, for 26,701,287 voting rights in total.
The financial instruments position includes a Right to Recall over 450,000 voting rights and multiple cash-settled swap positions totaling 6,034,406 voting rights with expiration dates between 2026 and 2030.
Smith & Nephew plc reports purchases of its Smith & Nephew plc SPON ADR American Depositary Shares on the New York Stock Exchange by three senior leaders under the Company's Employee Stock Purchase Plan on 10 July 2026 at a price of $24.48 per ADS.
Deepak Nath (Chief Executive Officer) and Paul Connolly (President, Global Operations) each acquired 434.02369 ADS, while Scott Schaffner (President, Sports Medicine) acquired 256.65972 ADS. The disclosure is made in accordance with the UK Market Abuse Regulation for Persons Discharging Managerial Responsibilities and persons closely associated with them.
Smith & Nephew plc has applied to the London Stock Exchange for 150,000 ordinary shares of US20¢ each to be admitted to trading. The shares are expected to start trading on 6 July 2026.
The new shares are reserved under a block admission and will be used to settle awards made under the company’s employee share plans. Once issued, they will rank pari passu, meaning they will have the same rights, benefits, and status as the existing ordinary shares already in circulation.
Smith & Nephew plc reports its updated share capital and voting rights position as at 30 June 2026. The company has total issued share capital of 877,733,750 ordinary shares of US20¢ each, which includes 32,697,503 ordinary shares held in treasury.
Because treasury shares do not carry voting rights, the company’s share capital with voting rights consists of 845,036,247 ordinary shares, each carrying one vote. Shareholders are advised to use this figure as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports a TR-1 notification of major holdings showing that an investor group linked to Cevian Capital has increased its position in the company.
The total holding now represents 13.206621% of voting rights, equal to 111,788,454 voting rights, up from a previously notified level of 13.056468%. All voting rights are attached directly to shares, with no additional exposure through financial instruments. The holding is split between Cevian Capital II Master Fund L.P. at 12.018425% and Cevian Capital II Co-Investment - Series P L.P. at 1.188196%, both controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc reports a TR-1 notification of major holdings showing that entities related to Cevian Capital have increased their stake in the company. The notification discloses that a total of 110,517,469 voting rights are now held, representing 13.056468% of Smith & Nephew’s voting rights, up from a previously reported 12.235936%. All voting rights are held through shares rather than financial instruments, indicating a purely equity-based position. The holding is structured primarily through Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment - Series P L.P., which together account for the disclosed percentage.
Cevian Capital II GP Limited reports beneficial ownership of 110,804,501 Ordinary Shares of Smith & Nephew plc, representing 13.09% of the company’s outstanding shares. The stake gives Cevian sole voting and dispositive power over these shares.
The shares were acquired for approximately USD $1,533,290,892, funded from the Cevian funds’ general working capital. The ownership percentage is based on 846,457,637 Ordinary Shares outstanding as of June 18, 2026, as disclosed on Smith & Nephew’s website.
Smith & Nephew plc reports a TR-1 notification of major holdings. Aurora Nominees Limited now holds 103,717,469 indirect voting rights in the company, representing 12.235936% of total voting rights, up from 12.074433% previously. The holding is linked to funds controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc reports a TR-1 notification showing that funds managed by Cevian Capital now control 12.074433% of its voting rights, representing 102,493,881 voting rights attached to shares. This stake is held indirectly, with no additional voting rights through financial instruments.
The holding has increased from a previously notified level of 11.183442%. The position is primarily held via Cevian Capital II Master Fund L.P. with 10.889586% of voting rights and Cevian Capital II Co-Investment - Series P L.P. with 1.184847%, both ultimately controlled by Cevian Capital II G.P. Limited.